PURPOSE: To derive a magnetic resonance (MR)-based imaging metric that reflects local perfusion changes resulting from the administration of angiogenic-inhibiting chemotherapy in patients with recurrent glioblastoma multiforme (GBM). MATERIALS AND METHODS: In this retrospective Institutional Review Board-approved HIPAA-compliant study, 16 patients (12 men, four women; mean age, 51.8 years + or - 15.1 [standard deviation]) with recurrent GBM received bevacizumab every 3 weeks (15 mg per kilogram of body weight) as part of a clinical trial. Baseline MR images were acquired, and follow-up images were acquired every 6 weeks thereafter until tumor progression or death. Imaging included perfusion and T1-weighted contrast material-enhanced MR imaging. Perfusion images were analyzed both with and without correction for contrast material leakage. The volumes of interest were selected as enhancing voxels on T1-weighted contrast-enhanced MR images. Relative cerebral blood volume (rCBV) maps were created from analysis of MR perfusion images. The volumes of interest were used to calculate the following parameters: size, mean rCBV, mean leakage coefficient K(2), and hyperperfusion volume (HPV), which is the fraction of the tumor with an rCBV higher than a predetermined threshold. Percent change in each parameter from baseline to first follow-up was compared with time to progression (TTP) by using a Cox proportional hazards model with calculation of hazard ratios. RESULTS: The most significant hazard ratio was seen with a DeltaHPV cutoff of rCBV greater than 1.00 (hazard ratio, 1.077; 95% confidence interval: 1.026, 1.130; P = .002). The only significant ratios greater than one were those that resulted from perfusion calculated as mean rCBV and DeltaHPV. The ratios were also higher after correction for leakage. CONCLUSION: This pilot study derived an imaging metric (HPV) that reflects local perfusion changes in GBMs. This metric was found to show a significantly improved correlation to TTP as compared with more commonly used metrics.
PURPOSE: To derive a magnetic resonance (MR)-based imaging metric that reflects local perfusion changes resulting from the administration of angiogenic-inhibiting chemotherapy in patients with recurrent glioblastoma multiforme (GBM). MATERIALS AND METHODS: In this retrospective Institutional Review Board-approved HIPAA-compliant study, 16 patients (12 men, four women; mean age, 51.8 years + or - 15.1 [standard deviation]) with recurrent GBM received bevacizumab every 3 weeks (15 mg per kilogram of body weight) as part of a clinical trial. Baseline MR images were acquired, and follow-up images were acquired every 6 weeks thereafter until tumor progression or death. Imaging included perfusion and T1-weighted contrast material-enhanced MR imaging. Perfusion images were analyzed both with and without correction for contrast material leakage. The volumes of interest were selected as enhancing voxels on T1-weighted contrast-enhanced MR images. Relative cerebral blood volume (rCBV) maps were created from analysis of MR perfusion images. The volumes of interest were used to calculate the following parameters: size, mean rCBV, mean leakage coefficient K(2), and hyperperfusion volume (HPV), which is the fraction of the tumor with an rCBV higher than a predetermined threshold. Percent change in each parameter from baseline to first follow-up was compared with time to progression (TTP) by using a Cox proportional hazards model with calculation of hazard ratios. RESULTS: The most significant hazard ratio was seen with a DeltaHPV cutoff of rCBV greater than 1.00 (hazard ratio, 1.077; 95% confidence interval: 1.026, 1.130; P = .002). The only significant ratios greater than one were those that resulted from perfusion calculated as mean rCBV and DeltaHPV. The ratios were also higher after correction for leakage. CONCLUSION: This pilot study derived an imaging metric (HPV) that reflects local perfusion changes in GBMs. This metric was found to show a significantly improved correlation to TTP as compared with more commonly used metrics.
Authors: B R Rosen; J W Belliveau; B R Buchbinder; R C McKinstry; L M Porkka; D N Kennedy; M S Neuder; C R Fisel; H J Aronen; K K Kwong Journal: Magn Reson Med Date: 1991-06 Impact factor: 4.668
Authors: K M Donahue; R M Weisskoff; D A Chesler; K K Kwong; A A Bogdanov; J B Mandeville; B R Rosen Journal: Magn Reson Med Date: 1996-12 Impact factor: 4.668
Authors: Kathleen M Schmainda; Scott D Rand; Allen M Joseph; Rebecca Lund; B Doug Ward; Arvind P Pathak; John L Ulmer; Michael A Badruddoja; Michael A Baddrudoja; Hendrikus G J Krouwer Journal: AJNR Am J Neuroradiol Date: 2004-10 Impact factor: 3.825
Authors: Meng Law; Stanley Yang; James S Babb; Edmond A Knopp; John G Golfinos; David Zagzag; Glyn Johnson Journal: AJNR Am J Neuroradiol Date: 2004-05 Impact factor: 3.825
Authors: A Gregory Sorensen; Tracy T Batchelor; Wei-Ting Zhang; Poe-Jou Chen; Priscilla Yeo; Meiyun Wang; Dominique Jennings; Patrick Y Wen; Johanna Lahdenranta; Marek Ancukiewicz; Emmanuelle di Tomaso; Dan G Duda; Rakesh K Jain Journal: Cancer Res Date: 2009-06-23 Impact factor: 12.701
Authors: B R Rosen; J W Belliveau; H J Aronen; D Kennedy; B R Buchbinder; A Fischman; M Gruber; J Glas; R M Weisskoff; M S Cohen Journal: Magn Reson Med Date: 1991-12 Impact factor: 4.668
Authors: D Daniels; D Guez; D Last; C Hoffmann; D Nass; A Talianski; G Tsarfaty; S Salomon; A A Kanner; D T Blumenthal; F Bokstein; S Harnof; D Yekutieli; S Zamir; Z R Cohen; L Zach; Y Mardor Journal: AJNR Am J Neuroradiol Date: 2016-07-07 Impact factor: 3.825
Authors: H S Nguyen; N Milbach; S L Hurrell; E Cochran; J Connelly; J A Bovi; C J Schultz; W M Mueller; S D Rand; K M Schmainda; P S LaViolette Journal: AJNR Am J Neuroradiol Date: 2016-08-04 Impact factor: 3.825
Authors: Fatima Tensaouti; Jonathan Khalifa; Amélie Lusque; Benjamin Plas; Jean Albert Lotterie; Isabelle Berry; Anne Laprie; Elizabeth Cohen-Jonathan Moyal; Vincent Lubrano Journal: Neuroradiology Date: 2017-08-25 Impact factor: 2.804
Authors: Benjamin Lemasson; Thomas L Chenevert; Theodore S Lawrence; Christina Tsien; Pia C Sundgren; Charles R Meyer; Larry Junck; Jennifer Boes; Stefanie Galbán; Timothy D Johnson; Alnawaz Rehemtulla; Brian D Ross; Craig J Galbán Journal: Transl Oncol Date: 2013-12-01 Impact factor: 4.243